The estimated Net Worth of Matthew W Foehr is at least $22.2 Million dollars as of 13 May 2022. Mr. Foehr owns over 2,500 units of Ligand Pharmaceuticals stock worth over $17,871,064 and over the last 14 years he sold LGND stock worth over $95,550. In addition, he makes $4,244,910 as President and Chief Operating Officer at Ligand Pharmaceuticals.
Matthew has made over 46 trades of the Ligand Pharmaceuticals stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 2,500 units of LGND stock worth $206,900 on 13 May 2022.
The largest trade he's ever made was exercising 45,547 units of Ligand Pharmaceuticals stock on 3 February 2021 worth over $1,050,769. On average, Matthew trades about 5,688 units every 40 days since 2011. As of 13 May 2022 he still owns at least 173,354 units of Ligand Pharmaceuticals stock.
You can see the complete history of Mr. Foehr stock trades at the bottom of the page.
Matthew (Matt) W. Foehr serves as President, Chief Operating Officer of the Company. rior to that time, Mr. Foehr served as our Executive Vice President and Chief Operating Officer since 2011, and has more than 20 years of experience managing global research and development programs. Prior to joining our company in 2011, he was Vice President and Head of Consumer Dermatology R&D, as well as Acting Chief Scientific Officer of Dermatology, in the Stiefel division of GlaxoSmithKline (GSK). Following GSK’s $3.6 billion acquisition of Stiefel in 2009, Mr. Foehr led the R&D integration of Stiefel into GSK. At Stiefel Laboratories, Inc., Mr. Foehr served as Senior Vice President of Global R&D Operations, Senior Vice President of Product Development & Support, and Vice President of Global Supply Chain Technical Services. Prior to Stiefel, Mr. Foehr held various executive roles at Connetics Corporation including Senior Vice President of Technical Operations and Vice President of Manufacturing. Mr. Foehr serves on the Board of Directors of Viking Therapeutics, Inc., a publicly-traded biotechnology company and Ritter Pharmaceuticals, Inc., a publicly-traded pharmaceutical company. Mr. Foehr is the author of multiple scientific publications and is named on numerous U.S. patents.
As the President and Chief Operating Officer of Ligand Pharmaceuticals, the total compensation of Matthew Foehr at Ligand Pharmaceuticals is $4,244,910. There are 1 executives at Ligand Pharmaceuticals getting paid more, with John Higgins having the highest compensation of $6,770,380.
Matthew Foehr is 47, he's been the President and Chief Operating Officer of Ligand Pharmaceuticals since 2015. There are 15 older and 2 younger executives at Ligand Pharmaceuticals. The oldest executive at Ligand Pharmaceuticals, Inc. is John Lamattina, 70, who is the Independent Director.
Matthew's mailing address filed with the SEC is C/O VIKING THERAPEUTICS, INC., 9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA, 92121.
Over the last 21 years, insiders at Ligand Pharmaceuticals have traded over $205,340,014 worth of Ligand Pharmaceuticals stock and bought 2,116,600 units worth $27,601,439 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog..., and Partners L P/Ilbiotechnolog.... On average, Ligand Pharmaceuticals executives and independent directors trade stock every 22 days with the average trade being worth of $2,239,733. The most recent stock trade was executed by Octavio Espinoza on 28 August 2024, trading 753 units of LGND stock currently worth $50,090.
ligand, a pharmaceutical company, is assembling a large and diverse portfolio of current and near-term commercial revenue generating assets to assist the long-term financial growth of the company. we operate this business on a lean cost structure that allows us to maximize cash flow and ultimately deliver a meaningful return for our shareholders.
Ligand Pharmaceuticals executives and other stock owners filed with the SEC include: